These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 15312242

  • 1. Serotonin regulates osteoclast differentiation through its transporter.
    Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P.
    J Bone Miner Res; 2004 Sep; 19(9):1420-31. PubMed ID: 15312242
    [Abstract] [Full Text] [Related]

  • 2. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K.
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [Abstract] [Full Text] [Related]

  • 3. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P, Tu Q, Chen J.
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD, Horwood NJ, Chuman Y, Fisher JL, Ellis J, Martin TJ, Rubin JS, Gillespie MT.
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [Abstract] [Full Text] [Related]

  • 6. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [Abstract] [Full Text] [Related]

  • 7. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R, Ransjö M, Tatarczuch L, Song SJ, Pagel C, Morrison JR, Pike RN, Mackie EJ.
    J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
    [Abstract] [Full Text] [Related]

  • 8. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [Abstract] [Full Text] [Related]

  • 9. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL.
    Kawaida R, Ohtsuka T, Okutsu J, Takahashi T, Kadono Y, Oda H, Hikita A, Nakamura K, Tanaka S, Furukawa H.
    J Exp Med; 2003 Apr 21; 197(8):1029-35. PubMed ID: 12707301
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF.
    Biochem Pharmacol; 2005 Jul 15; 70(2):300-7. PubMed ID: 15919055
    [Abstract] [Full Text] [Related]

  • 11. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
    Merle B, Itzstein C, Delmas PD, Chenu C.
    J Cell Biochem; 2003 Oct 01; 90(2):424-36. PubMed ID: 14505357
    [Abstract] [Full Text] [Related]

  • 12. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.
    Zhonghua Yi Xue Za Zhi; 2004 Dec 17; 84(24):2102-6. PubMed ID: 15730627
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E.
    Bone; 2005 Jan 17; 36(1):159-72. PubMed ID: 15664014
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
    Park EK, Kim MS, Lee SH, Kim KH, Park JY, Kim TH, Lee IS, Woo JT, Jung JC, Shin HI, Choi JY, Kim SY.
    Biochem Biophys Res Commun; 2004 Dec 24; 325(4):1472-80. PubMed ID: 15555594
    [Abstract] [Full Text] [Related]

  • 17. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K.
    Biochem Biophys Res Commun; 2005 Mar 04; 328(1):91-7. PubMed ID: 15670755
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
    Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Offord E, Brazier M.
    J Cell Biochem; 2004 May 15; 92(2):285-95. PubMed ID: 15108355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.